Recorded Presentations from the NCCN 2018 Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™

The management of cancer is constantly evolving through the introduction of new developments related to cancer treatment and supportive care. This program will provide hematology/oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Information is focused on current and critical issues to provide hematology/oncology nurses with practical information that can be implemented in the practice setting. The program content will address the following topics:  Optimizing the Care of Patients Receiving CAR T-Cell Therapy; Management of Toxicities Associated with Immune Checkpoint Inhibitors; Strategies to Identify Needs and Coordinate Referrals to a Multidisciplinary Chronic Graft-Versus-Host Clinic, and Transition of Care: Homebound Stem Cell Transplantation.

The goal of this activity is to ensure that hematology/oncology nurses, as members of the interprofessional oncology team, have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with hematologic malignancies.

This information was originally presented at the NCCN 2018 Nursing Forum: Oncology Nursing in Hematologic Malignancies held in New York, New York, on September 21, 2018.

Target Audience

This educational program is designed to meet the educational needs of hematology/oncology nurses who manage patients with hematologic malignancies.

Learning Objectives

Following this program, participants should be able to:

  • Evaluate advances in the management of patients with hematologic malignancies and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and apply appropriate treatment and supportive care strategies to optimize patient education and care.  
  • Review issues related to toxicities and adverse events associated with therapy with CAR T cells, immune checkpoint inhibitors, and hematopoietic cell transplantation and implement appropriate strategies for managing these in the healthcare setting.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Celgene Corporation
  • Genentech
  • Jazz Pharmaceuticals, Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

This educational activity is supported by a medical education grant from Karyopharm Therapeutics.

This educational activity is supported by an independent educational grant from Incyte.

This educational activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

Course summary
Course opens: 
11/01/2018
Course expires: 
11/01/2019
Cost:
$0.00

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education (CE) activities are expected to disclose any relevant financial relationships with a commercial interest as defined by ACCME’s, ACPE’s, and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

These activities are approved for nursing contact hours. Complete accreditation information is provided before each individual educational activity.

Available Credit

Accreditation Period

Course opens: 
11/01/2018
Course expires: 
11/01/2019
 
Status
Price
Title
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.

Price

Cost:
$0.00
Please login or register to take this course.